{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:44:55Z","timestamp":1790714695731,"version":"4.1.0"},"reference-count":68,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Looking back at 2024, the authors highlight the top five clinical advances in bladder cancer (urothelial carcinoma), from: (1) novel drug\u2010delivery mechanisms in intravesical therapy for nonmuscle\u2010invasive bladder cancer and muscle\u2010invasive bladder cancer (MIBC); (2) immune checkpoint inhibition (ICI) as adjuvant and (3) perioperative therapy in MIBC; (4) circulating tumor DNA as a biomarker in MIBC; to (5) a new standard of care in first\u2010line metastatic urothelial carcinoma. TAR\u2010200 is a new intravesical drug\u2010delivery system that enables controlled release of gemcitabine but may be used with other anticancer drugs to treat nonmuscle\u2010invasive bladder cancer and MIBC. Two phase 3 studies of adjuvant ICI (nivolumab and pembrolizumab) have both reported a doubling of disease\u2010free survival in patients with high\u2010risk MIBC receiving therapy. Perioperative durvalumab, including neoadjuvant therapy plus gemcitabine and cisplatin before radical cystectomy followed by adjuvant durvalumab, demonstrated an improvement in event\u2010free survival and overall survival for patients with MIBC. Circulating tumor DNA is a promising biomarker to select patients with MIBC for adjuvant ICI therapy. Finally, the combination of enfortumab vedotin, an antibody\u2013drug conjugate, plus pembrolizumab doubled overall survival compared with standard gemcitabine plus platinum in patients with metastatic urothelial carcinoma and has been implemented in treatment guidelines in the United States, Europe, and Asia as the new standard of care in this setting, transforming the treatment landscape for bladder cancer.<\/jats:p>","DOI":"10.1002\/cncr.70020","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T16:29:14Z","timestamp":1754756954000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Top advances of the year: Bladder cancer"],"prefix":"10.1002","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9409-1836","authenticated-orcid":false,"given":"Andrea B.","family":"Apolo","sequence":"first","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Atiq","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-8457","authenticated-orcid":false,"given":"Andre R.","family":"Kydd","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Chelluri","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-8568","authenticated-orcid":false,"given":"Braden","family":"Millan","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-9269","authenticated-orcid":false,"given":"Sandeep","family":"Gurram","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Chandran","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Simon","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch Center for Cancer Research National Cancer Institute National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.02.009"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200167"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.015"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200092"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02510"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003977"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj970"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.264"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.01.013"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003195"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201001651"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2328"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2825"},{"key":"e_1_2_11_16_1","volume-title":"SunRISe\u20105: a phase 3, randomized, open\u2010label study of TAR\u2010200 compared with intravesical chemotherapy after Bacillus Calmette\u2010Guerin in recurrent high\u2010risk non\u2010muscle\u2013invasive bladder cancer","author":"Porten S","year":"2024"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000001994.17"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0001015816.87470.c9.02"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0001015816.87470.c9.08"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.tps715"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001008712.53259.7d.02"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003981"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00587\u20109"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034442"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2401726"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.049"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00004\u20108"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00340"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010021\u201003642\u20109"},{"key":"e_1_2_11_31_1","volume-title":"Paper presented at: European Association of Urology Congress; April 5\u20138","author":"Powles T","year":"2024"},{"issue":"2","key":"e_1_2_11_32_1","first-page":"S1135","article-title":"Identification of bladder cancer patients that could benefit from early post\u2010cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial [abstract]","volume":"35","author":"Jensen J","year":"2024","journal-title":"Ann Oncol"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2408154"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312117"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.6_suppl.tps599"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102019\u20100611"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.6_suppl.tps585"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.6_suppl.tps588"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.6_suppl.tps579"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.6_suppl.tps506"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.4568"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2108"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.34.8433"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.17.3068"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2002788"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00152\u20102"},{"key":"e_1_2_11_47_1","volume-title":"FDA grants accelerated approval to enfortumab vedotin\u2010ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma","author":"US Food and Drug Administration (FDA)","year":"2023"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01643"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00540\u20105"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30541\u20106"},{"key":"e_1_2_11_52_1","volume-title":"Corporate news details: Bristol Myers Squibb Provides Update on CheckMate\u2010901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First\u2010Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma","author":"Bristol Myers Squibb Company","year":"2022"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2309863"},{"key":"e_1_2_11_54_1","volume-title":"FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"e_1_2_11_55_1","volume-title":"Padcev Package insert: Summary of Product Characteristics","author":"European Medicines Agency (EMA)","year":"2022"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2308849"},{"key":"e_1_2_11_57_1","volume-title":"FDA grants accelerated approval to fam\u2010trastuzumab deruxtecan\u2010nxki for unresectable or metastatic HER2\u2010positive solid tumors","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02005"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.830"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112431"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00064\u20100"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00380\u20102"},{"key":"e_1_2_11_63_1","volume-title":"NCCN Guidelines: Bladder Cancer","author":"National Comprehensive Cancer Network (NCCN)","year":"2024"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201020\u20102488"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02912"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.tps717"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.3038"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03489"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.603"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:44:16Z","timestamp":1760406256000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":68,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,15]]}},"alternative-id":["10.1002\/cncr.70020"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70020","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"2025-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70020"}}